CASE OF USING THE INHIBITOR OF INTERLEUKIN 1 CANACINUMAB IN PATIENTS WITH AUTO INFLAMMATORY DISEASES

CASE OF USING THE INHIBITOR OF INTERLEUKIN 1 CANACINUMAB IN PATIENTS WITH AUTO INFLAMMATORY DISEASES

Interleukin 1 (IL 1) is the main mediator for many auto inflammatory diseases (AID). Cryopyrin-associated periodic syndromes (CAPS) became the first diseases, for which the efficacy of IL 1 inhibitors was shown with a high degree of evidence. Canacinumb (totally human monoclonal antibodies to IL 1 i...

Full description

Saved in:

Bibliographic Details
Main Authors:	S. O. Salugina, E. S. Fedorov, N. N. Kuz'mina, E. Yu. Zakharova
Format:	Article
Language:	Russian
Published:	Union of pediatricians of Russia 2015-04-01
Series:	Педиатрическая фармакология
Subjects:	cryopyrin-associated periodic syndromes periodic syndrome associated with the tumor necrosis factor receptor gene mutation treatment canakinumab il 1inhibitors
Online Access:	https://www.pedpharma.ru/jour/article/view/11
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The interleukin 1 inhibitor canakinumab in the treatment of cryopyrin-associated periodic syndromes (CAPS): clinical experience
by: Svetlana Olegovna Salugina, et al.
Published: (2014-12-01)

Current approaches to diagnosis, treatment, and monitoring in patients with cryopyrin-associated periodic syndromes (CAPS)
by: S. O. Salugina, et al.
Published: (2016-06-01)

A familial case of Muckle-Wells syndrome in a Russian population: The first successes of therapy with the interleukin 1 inhibitor canakinumab
by: S. O. Salugina, et al.
Published: (2015-03-01)

CINCA/NOMID is a rare autoinflammatory syndrome in rheumatological practice. Experience of diagnosis, management and therapy with interleukin-1 inhibitors
by: S. O. Salugina, et al.
Published: (2024-04-01)

DIAGNOSIS AND TREATMENT OF PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
by: A. L. Kozlova, et al.
Published: (2015-04-01)

Low-penetrance R92Q (p.Arg121Gln) mutation in the <i>TNFRSF1A</i> gene: the significance and variants of phenotypes. Successful experience with the interleukin-1 inhibitor canakinumab in a female patient, who is a carrier of R92Q mutation with a severe TRAPS phenotype
by: E. S. Fedorov, et al.
Published: (2020-09-01)

EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)
by: T. V. Sleptsova, et al.
Published: (2014-05-01)

Cryopyrin-Associated Periodic Syndrome (CAPS) Caused by c.943A>G Variant of NLRP3 Gene: Clinical Case
by: Ivan A. Kriulin, et al.
Published: (2019-11-01)

Muckle–Wells Syndrome in a Child With Recurrent Urticaria
by: Elena M. Kamaltynova, et al.
Published: (2017-06-01)

Adult onset cryopyrin-associated periodic syndrome due to germline missense mutation in NLRP3 in a previously healthy middle-aged woman
by: Sung Ik Cho, et al.
Published: (2025-08-01)

CRYOPYRIN ASSOCIATED PERIODIC SYNDROME
by: M. Gattorno
Published: (2013-02-01)

From Urticaria to Correct Diagnosis: A Case Report of Cryopyrin-Associated Periodic Syndromes
by: Wang X, et al.
Published: (2025-04-01)

Autoimmune/autoinflammatory syndrome induced by adjuvants after multi-component meningococcal serogroup B vaccination in a 7-year-old girl: a case report
by: Özge Atay, et al.
Published: (2022-04-01)

CANAKINUMAB IN THE TREATMENT OF RHEUMATIC DISEASES IN CHILDREN
by: Ye. I. Alekseeva, et al.
Published: (2014-12-01)

How to identify a patient with autoinflammatory syndrome: Clinical and diagnostic algorithms
by: Mikhail Mikhailovich Kostik, et al.
Published: (2013-10-01)

Use of Anakinra in Patients with Cryopyrin-Associated Periodic Syndromes and Other Autoinflammatory Diseases
by: Mikhail M. Kostik
Published: (2016-12-01)

Use of anakinra in cryopyrin-associated periodic syndromes: case report and review of literature
by: Marta Salas Sánchez, et al.
Published: (2025-06-01)

Comprehensive Clinical Analysis of Rilonacept in the Treatment of Cryopyrin-Associated Periodic Syndromes: A Systematic Review
by: Zhang T, et al.
Published: (2025-05-01)

Cryopyrin-Associated Periodic Syndromes (CAPS): Pathogenesis, Clinical Manifestations, and IL-1-Targeted Therapeutic Strategies
by: Joanna Nadaj, et al.
Published: (2025-07-01)

Infection or autoinflammatory disease? Difficulties of differential diagnosis on the example of a carrier of the Q705K variant of the NLRP3 gene
by: A. S. Levina, et al.
Published: (2025-03-01)

Evaluation of common NLRP3 Q703K variant in pediatric patients with autoinflammatory disease: CAPS and PFAPA
by: Yasemin Kendir-Demirkol, et al.
Published: (2023-08-01)

A patient heterozygous for R92Q mutation with periodic fever and aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome-like phenotype
by: Ezgi Deniz Batu, et al.
Published: (2018-12-01)

Familial Mediterranean fever (periodic disease): history or a real problem
by: E. S. Fedorov, et al.
Published: (2018-09-01)

Schnitzler’s syndrome – diagnostic experience, approaches to therapy, patient management according to a multicenter Russian cohort
by: S. O. Salugina, et al.
Published: (2024-01-01)

Cryopyrin-associated periodic syndrome Muckle — Wells: A Case Report
by: N. V. Shakhova, et al.
Published: (2023-07-01)

Case Report: A heterozygous mutation of NLRP3 in a Chinese child with NLRP3-AID
by: Yangming Ruan, et al.
Published: (2025-08-01)

The Fever Mystery: Unraveling Tumor Necrosis Factor Receptor-associated Periodic Fever Syndrome as the Instigator of Secondary Renal Amyloidosis
by: Arjun Agarwal, et al.
Published: (2023-10-01)

Clinical experience with the interleukin-1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used
by: M. S. Eliseev, et al.
Published: (2015-06-01)

EXPERIENCE OF ADMINISTRATION OF CANAKINUMAB, AN INTERLEUKIN 1β INHIBITOR, IN A PATIENT WITH CHRONIC TOPHACACEOUS GOUT
by: Maksim Sergeyevna Eliseev, et al.
Published: (2014-03-01)

Administration of the Interleukin-1 Inhibitor Canakinumab in Children with Autoinflammatory Diseases and Systemic Juvenile Arthritis: the Report for Case Series
by: S. O. Salugina, et al.
Published: (2016-02-01)

Clinical and Genetic Characteristics, Target Therapy Results in Children with Traps Syndrome (on Clinical Surveillance Data)
by: E. V. Antsiferova, et al.
Published: (2021-09-01)

EXPERIENCE OF THE SUCCESSFUL CANAKINUMAB TREATMENT OF A PATIENT WITH UNDIFFERENTIATED AUTOINFLAMMATORY SYNDROME
by: Tatyana V. Sleptsova, et al.
Published: (2016-11-01)

Results of molecular genetic screening of mutations in the NLRP3, TNFRSF1A, and MVK genes in patients with autoinflammatory diseases and systemic juvenile arthritis
by: S. O. Salugina, et al.
Published: (2017-09-01)

The use of an interleukin 1 inhibitor in a patient with atypical course of periodic fever
by: M. S. Eliseev, et al.
Published: (2021-06-01)

Treating TRAPS Syndrome with a Previously Undescribed TNF α Gene Receptor Mutation Successfully with Canakinumab
by: T. V. Sleptsova, et al.
Published: (2016-11-01)

The role of interleukin 1 in the development of human diseases
by: E. L. Nasonov
Published: (2019-04-01)

Migraine and its childhood equivalents
by: P. V. Zhmyleva, et al.
Published: (2023-12-01)

Assessment of cardiovascular risk from the use of an interleukin-1 inhibitor in patients with severe tophaceous gout
by: M. S. Eliseev, et al.
Published: (2016-03-01)

Clinical and diagnostic manifestations in women of reproductive age having both hyperthyroidism and hyperandrogenism
by: N. E. Akhundova
Published: (2020-01-01)

Familial Mediterranean Fever: Current Approaches to Diagnosis and Treatment
by: Mikhail M. Kostik, et al.
Published: (2018-12-01)